Combined modality treatments in pancreatic cancer

被引：10

作者：

Lombardi, Lucia ^{[1
]}

Troiano, Michele ^{[2
]}

Silvestris, Nicola ^{[3
]}

Nanni, Luciano ^{[1
]}

Latiano, Tiziana Pia ^{[1
]}

Di Maggio, Gabriele ^{[1
]}

Cinieri, Saverio ^{[4
]}

Di Sebastiano, Pierluigi ^{[5
]}

Colucci, Giuseppe ^{[3
]}

Maiello, Evaristo ^{[1
]}

机构：

[1] IRCCS Casa Sollievo Sofferenza, Oncol Unit, San Giovanni Rotondo, FG, Italy

[2] IRCCS Casa Sollievo Sofferenza, Radiat Therapy Unit, San Giovanni Rotondo, FG, Italy

[3] Natl Canc Inst Giovanni Paolo II, Med & Expt Oncol Unit, Bari, Italy

[4] Perrino Hosp, Med Oncol Unit, Brindisi, Italy

[5] IRCCS Casa Sollievo Sofferenza, Surg Unit, San Giovanni Rotondo, FG, Italy

来源：

EXPERT OPINION ON THERAPEUTIC TARGETS | 2012年 / 16卷

关键词：

adjuvant therapy; chemoradiotherapy; neoadjuvant therapy; pancreatic cancer; GEMCITABINE-BASED CHEMORADIATION; PHASE-III TRIAL; RESECTABLE ADENOCARCINOMA; SURGICAL RESECTION; PREOPERATIVE CHEMORADIATION; NEOADJUVANT THERAPY; RADIATION-THERAPY; CHEMOTHERAPY; CISPLATIN; CHEMORADIOTHERAPY;

D O I：

10.1517/14728222.2012.662959

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Introduction: Of all the carcinomas, pancreatic carcinoma (PC) has the highest mortality rate, with a 1- and 5-year survival rate of 25% and less than 5% respectively. This is regardless of the stage at diagnosis. Areas covered: In this review relevant literature assessing the evidence regarding preoperative and adjuvant chemoradiotherapy (CRT) is discussed. Furthermore, new therapeutic approaches are summarized, while the future direction regarding the multimodality approach to PC is also discussed. Expert opinion: The role of combined-modality therapy for PC is continuously evolving. There have been several recent developments, as well as the completion of major, multi-institutional clinical trials. One of the challenges for the busy clinician is to appreciate the variation in staging, surgical expertise, and application of either definitive CRT or neo-adjuvant CRT for local and/or borderline disease.

引用

页码：S71 / S81

页数：11

共 50 条

[1] Combined modality therapy for pancreatic cancer
Tsai, JY
Iannitti, DA
Safran, H
[J]. SEMINARS IN ONCOLOGY, 2003, 30 (04) : 71 - 79
[2] Pancreatic cancer - the role of systemic and combined modality treatment
Kubicka-Wolkowska, Joanna
Czyzykowski, Rafal
Debska-Szmich, Sylwia
Lisik-Habib, Maja
Potemski, Piotr
[J]. ONCOLOGY IN CLINICAL PRACTICE, 2014, 10 (03): : 152 - 159
[3] Combined treatments improve pancreatic cancer survival
不详
[J]. EUROPEAN JOURNAL OF CANCER, 2006, 42 (01) : 2 - 2
[4] SURVIVAL AFTER COMBINED MODALITY THERAPY FOR PANCREATIC-CANCER
BRUCKNER, HW
KALNICKI, S
DALTON, J
SNADY, H
SCHWARTZ, GK
CHESSER, MR
LEHRER, D
MANDELI, J
HARPAZ, N
JANUS, C
[J]. JOURNAL OF CLINICAL GASTROENTEROLOGY, 1993, 16 (03) : 199 - 203
[5] PREOPERATIVE COMBINED-MODALITY THERAPY FOR PANCREATIC-CANCER
RICH, TA
EVANS, DB
[J]. WORLD JOURNAL OF SURGERY, 1995, 19 (02) : 264 - 269
[6] COMBINED MODALITY TREATMENT OF PANCREATIC-CANCER - IMPLICATIONS FOR THE SURGEON
METZGER, UF
KISNER, DL
GHOSH, BC
[J]. JOURNAL OF SURGICAL ONCOLOGY, 1983, 24 (02) : 107 - 112
[7] Intraoperative radiotherapy in the combined-modality management of pancreatic cancer
Schuricht, AL
Spitz, F
Barbot, D
Rosato, F
[J]. AMERICAN SURGEON, 1998, 64 (11) : 1043 - 1049
[8] Pleural mesothelioma: combined modality treatments
Giaccone, G
[J]. ANNALS OF ONCOLOGY, 2002, 13 : 217 - 225
[9] Hypoxia as a target for combined modality treatments
Wouters, BG
Weppler, SA
Koritzinsky, M
Landuyt, W
Nuyts, S
Theys, J
Chiu, RK
Lambin, P
[J]. EUROPEAN JOURNAL OF CANCER, 2002, 38 (02) : 240 - 257
[10] Recent Advances in Combined Modality Treatment for Locally Advanced Pancreatic Cancer
Aksu, Gorkem
Sarper, Binnaz
Ulutin, Cuneyt
Bakkal, Hakan
[J]. CURRENT CANCER THERAPY REVIEWS, 2005, 1 (03) : 227 - 237

← 1 2 3 4 5 →